Yes, you can add Forxiga (dapagliflozin) 10 mg to metformin XR 1 g when glucose remains uncontrolled.
Adding dapagliflozin 10 mg to metformin is FDA-approved, clinically proven, and represents standard second-line therapy for type 2 diabetes inadequately controlled on metformin monotherapy. 1
Evidence Supporting This Combination
The FDA label explicitly includes clinical trials demonstrating that dapagliflozin 10 mg added to metformin (≥1,500 mg/day) produces:
- HbA1c reduction of approximately 0.5-0.8% compared to placebo
- Weight loss of 3-4.5 kg over 24 weeks
- Systolic blood pressure reduction of 3-4 mmHg
- Sustained benefits maintained for up to 102 weeks 1, 2
Current Guideline Framework
The 2025 ADA Standards of Care support adding SGLT2 inhibitors like dapagliflozin when metformin monotherapy fails to achieve glycemic targets 3. The 2025 BMJ guideline notes that SGLT2 inhibitors and GLP-1 receptor agonists can be combined with metformin, though they emphasize cardiovascular/kidney risk stratification for optimal selection 4.
Practical Considerations
Dosing: Start dapagliflozin 10 mg once daily (the standard dose used in clinical trials with metformin) 1
Expected timeline: You should see HbA1c improvements within 12-24 weeks 2, 5
Safety profile to monitor:
- Genital mycotic infections (12-15% incidence) - usually mild and respond to standard treatment 2, 5
- Urinary tract infections (8-13% incidence) - similar to placebo in most studies 2
- Volume depletion - ensure adequate hydration, especially in elderly or those on diuretics
- Hypoglycemia risk is minimal when combined with metformin alone (3.5% vs 40.8% with sulfonylureas) 5
Common Pitfalls to Avoid
Do not delay adding dapagliflozin - therapeutic inertia is explicitly discouraged in current guidelines 3. If metformin alone isn't achieving target, intensify promptly.
Check renal function first - dapagliflozin requires adequate kidney function (eGFR considerations apply per FDA label)
Consider cardiovascular/kidney benefits - If your patient has established cardiovascular disease, chronic kidney disease, or heart failure, dapagliflozin offers additional organ protection beyond glucose lowering, making it an even stronger choice 4
Patient education is critical - Warn about genital hygiene to reduce infection risk, ensure adequate fluid intake, and explain the mechanism (urinary glucose loss) so patients understand why urination frequency may increase initially
The combination of metformin plus dapagliflozin is more effective than metformin monotherapy, causes weight loss rather than weight gain, and has minimal hypoglycemia risk compared to alternatives like sulfonylureas 5. This makes it an excellent second-line choice for your patient.